Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator

Luigi A.M.J.G. van Riel; Auke Jager; Dennie Meijer; Arnoud W. Postema; Ruth Smit; André N. Vis; Theo M. de Reijke; Harrie P. Beerlage; Jorg R. Oddens

doi:10.1177/17562872221088536

January 1, 2022Therapeutic Advances in UrologyOpen Access

Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator

View Full Paper

Ask AI

Bookmark

Share

Abstract

This is the authors' abstract. We don't add key points for this paper.

The developed RC (Prostate Biopsy Cohort Amsterdam ('PROBA' RC), integrated predictors for csPCa at prostate biopsy in negative-MRI men and outperformed other widely used RCs. These findings require external validation before introduction in daily practice.

Ask about this paper

Answers are grounded in this paper and cite their sources.

Discussion

No takes yet. Share an insight, caveat, or question.

Cite This Study

Riel et al. (2022) studied this question.

synapsesocial.com/papers/69d834beba18484428d187ca https://doi.org/10.1177/17562872221088536

View Full Paper

Ask AI

Bookmark

Share

Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator

Abstract

Ask about this paper

Discussion

Cite This Study

Predictors of clinically significant prostate cancer in biopsy-naïve and prior negative biopsy men with a negative prostate MRI: improving MRI-based screening with a novel risk calculator

Abstract

Ask about this paper

Discussion

Cite This Study

Keep reading

Keep reading